Interaction Between Rimonabant and Cyclosporine and Tacrolimus

NCT ID: NCT00525681

Last Updated: 2014-12-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-09-30
• Study Completion Date: 2008-05-31

Brief Summary

The major cause of premature death in renal transplant recipients is cardio-vascular disease. In addition, obesity is becoming a major problem in this patient population. Rimonabant does not only seem to have weight reducing properties but also weight reduction independent effects on insulin sensitivity and endothelial function, two important cardio-vascular risk factors. Rimonabant therefore is an interesting drug for the treatment of transplanted patients. Present data also indicate that rimonabant does not interact with essential immunosuppressive drugs (CsA and Tac) indicating that it most probably is safe to administer to this patient population. However this needs to be investigated in a proper manner.

Detailed Description

Renal transplant recipients are treated with life-long immunosuppressive therapy in order to prevent acute rejection episodes. The calcineurin inhibitors (CsA and Tac) are the back-bones in the immunosuppressive treatment and they have a very narrow therapeutic index. It is therefore essential to assure that new drug to be used in transplanted patients do not interact with CsA and Tac. Even though rimonabant is metabolized via the same enzyme as CsA and Tac (CYP3A4) previous in vitro and in vivo studies with relevant probe drugs in healthy volunteers do not indicate the presence of any relevant pharmacokinetic interaction. However, to be absolutely sure that it is safe to administer rimonabant in transplanted patients a 12-hour pharmacokinetic interaction investigation is included for 16 patients in the present pilot study (8 patients on CsA and 8 patients on Tac).

Conditions

Renal Transplantation

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CsA

Investigation of systemic exposure of cyclosporine before and after 2 moths of co-adminiastration of rimonabant.

Group Type: OTHER

cyclosporine A

Intervention Type: DRUG

Cyclosporine is dosed twice daily and is individualized as per center practice and kept stable during the study.

Tac

Investigation of systemic exposure of tacrolimus before and after 2 moths of co-adminiastration of rimonabant.

Group Type: OTHER

tacrolimus

Intervention Type: DRUG

Dosing of tacrolimus is given twice daily and individualized as per center practice.

Interventions

cyclosporine A

Cyclosporine is dosed twice daily and is individualized as per center practice and kept stable during the study.

Intervention Type: DRUG

tacrolimus

Dosing of tacrolimus is given twice daily and individualized as per center practice.

Intervention Type: DRUG

Other Intervention Names

Sandimmun Neoral; Prograf

Eligibility Criteria

Inclusion Criteria

• Renal transplant recipient with stable renal function (less than 20% deviation in serum creatinine the last 2 months).
• Renal transplant recipient currently on CsA or Tac and prednisolone based immunosuppression.
• BMI > 30 kg/m2 or >27 kg/m2 in combination with one or more cardio-vascular risk factors.
• > 18 years of age.
• Male patient, or female patient without childbearing potential (surgically sterilized or postmenopausal) or, if female of childbearing potential, is not lactating, has a negative pregnancy test at screening and is willing to utilize an effective method of contraception throughout the study period and for 90 Days following discontinuation of the Study Drugs.
• Signed informed consent.

Exclusion Criteria

• Diabetes mellitus
• Severe liver disease.
• Depressive-, anxiety- or sleeping disorders.
• Estimated GFR < 25 ml/min.
• Epilepsy.
• Skin disorders that may influence laser Doppler flowmetry investigations.
• Pregnant or nursing mothers.
• Concomitant treatment with CYP3A4 inhibitors (www.cyp450.no) with interaction potential according to the investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Oslo School of Pharmacy

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Anders Åsberg, Ph.D.

Role: STUDY_CHAIR

Scholl of Pharmacy, University of Oslo

Locations

Rikshospitalet, Section of Nephrology

Oslo, , Norway

Countries

Norway

Other Identifiers

RIMONA-PILOT

Identifier Type: -

Identifier Source: org_study_id